Bright Minds Biosciences (TSE:DRUG) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Bright Minds Biosciences has announced promising preclinical results for its compound BMB-201, which showed similar pain relief efficacy to morphine without the associated dependency risks. This development is a significant step in providing non-opioid alternatives for neuropathic pain management, with plans to advance into clinical trials.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
